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Abstract The computational design of a symmetric protein homo-oligomer that binds a
symmetry-matched small molecule larger than a metal ion has not yet been achieved. We used de
novo protein design to create a homo-trimeric protein that binds the C3 symmetric small molecule
drug amantadine with each protein monomer making identical interactions with each face of the
small molecule. Solution NMR data show that the protein has regular three-fold symmetry and
undergoes localized structural changes upon ligand binding. A high-resolution X-ray structure
reveals a close overall match to the design model with the exception of water molecules in the
amantadine binding site not included in the Rosetta design calculations, and a neutron structure
provides experimental validation of the computationally designed hydrogen-bond networks.
Exploration of approaches to generate a small molecule inducible homo-trimerization system based
on the design highlight challenges that must be overcome to computationally design such systems.
Introduction
While there has been progress in the de novo design of small molecule binding proteins
(Tinberg et al., 2013; Ollikainen et al., 2015; Mills et al., 2016; Polizzi et al., 2017; Dou et al.,
2018), there are still considerable challenges in this area (Dou et al., 2017). There has also been
progress in designing protein structures with internal symmetry (Boyken et al., 2016;
Ghirlanda et al., 2004). We focus in this paper on the challenge of designing symmetric protein
homo-oligomers that bind to symmetry matched small molecules such that each protein monomer
makes identical interactions with the small molecule. From the protein design standpoint, this chal-
lenge is interesting as it enables more economical design strategies in which one protein-small mole-
cule interface is utilized multiple times, analogous to the use of a single designed protein-protein
interface in self-assembling protein nanostructures (Bale et al., 2016; Hsia et al., 2016). From the
applications standpoint, the challenge has considerable importance because it provides a stepping
stone to ligand induced homo-oligomerization systems, which are increasingly in demand in cellular
engineering applications (Fegan et al., 2010; DeRose et al., 2013). Chemically-inducible dimeriza-
tion systems (Spencer et al., 1996) have been utilized to modulate signal transduction
(Spencer et al., 1996; Mallet et al., 2002; Guerrero et al., 2008), transcriptional activation
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(Nyanguile et al., 1997), and post-translational modification (Stankunas et al., 2003), and as com-
ponents for logic gates (Miyamoto et al., 2012). However, to our knowledge, no chemically-induc-
ible trimerization systems have been developed despite the importance of trimerization in pro-
apoptotic and pro-inflammatory signaling cascades (Spencer et al., 1996).
Results
Computational design strategy for ABP
We set out to design trimeric proteins that bind small molecules with three-fold symmetry on their
symmetry axes. We focused on the C3 symmetric compound amantadine as it is an FDA approved
drug (https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf)
with a low side effect profile (Perez-Lloret and Rascol, 2018). To de novo design amantadine-bind-
ing sites at the protein trimer C3 axes, we started from parametrically generated C3 symmetric heli-
cal bundle backbones consisting of two concentric rings each with three helices. The symmetry axes
of the protein scaffold and the amantadine were aligned, and the remaining two degrees of freedom
(the placement along the symmetry axis, and the rotation around this axis) were sampled by grid
search (Figure 1a). For each placement, RosettaDesign was used to optimize the identities and con-
formations of the residues within 12.5 A˚ of the amantadine for high affinity binding, and residue con-
formations at distances farther than 12.5 A˚ to retain hydrogen-bond networks identified by Rosetta
HBNet (Figure 1b–c). The search was restricted to symmetric solutions in which each monomer is
identical in sequence and structure. We found a particularly low energy solution starting from a pre-
viously characterized design with a high-resolution crystal structure (2L6HC3_13) (Boyken et al.,
2016) (Figure 1a and d). This solution, which we refer to as ABP (amantadine-binding protein), con-
tains 19 amino acid changes compared to 2L6HC3_13 (Figure 1d). The interactions critical for aman-
tadine binding include hydrogen bonds from Ser-71 to the polar amino group of amantadine and a
shape complementary binding pocket composed by Ile-64, Leu-67, and Ala-68 (Figure 1b).
Figure 1. Computational design methodology. (a) The homo-trimeric scaffold was designed to bind amantadine such that the C3 axes of the protein
and the small molecule are aligned. Amantadine is colored orange and each monomer of ABP is colored magenta, green, or cyan. The amantadine
binding site is highlighted by a dashed oval. (b) The binding pocket in ABP was designed to have polar serine residues (Ser-71) that hydrogen-bond
(yellow dashed lines) to the amino group of amantadine and nonpolar residues (Ile-64, Leu-67, and Ala-68) to complement the shape of the
hydrophobic moiety of amantadine. (c) The design model contains hydrogen-bond networks that specify the trimeric assembly of ABP. (d) A sequence
alignment of ABP and 2L6HC3_13 is shown, with mutated regions shown in black boxes. Both sequences are preceded by a five-residue GHSMG pre-
sequence (not shown) that result from the cloning strategy. The residues highlighted in (b) are annotated by green circles.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. ABP variant designs.
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Binding interaction of amantadine with ABP
A synthetic gene encoding ABP was obtained and the protein expressed in E. coli. The design was
expressed at high levels in the soluble fraction and was found by SEC-MALS to be a trimer in the
presence and absence of amantadine (Figure 2a). Interactions with amantadine were probed using
thermofluor dye binding assay (differential scanning fluorimetry). The thermofluor melting curve for
apo-ABP exhibited a high initial fluorescence signal at 25˚ C (Figure 2b), indicating that hydrophobic
residues in the protein core are exposed to solvent, characteristic of a molten globule state. As the
protein was heated to 95˚ C, the fluorescence signal decreased, likely due to aggregation and/or
complete unfolding. In the presence of amantadine (1 mM), the initial fluorescence signal was much
lower, characteristic of properly folded proteins (Figure 2b), suggesting that amantadine binding
may cause local ordering and exclude solvent. In contrast, 2L6HC3_13, which has the same back-
bone parameters but lacks the amantadine binding site, is thermally stable by thermofluor assay,
only starting to denature at ~80˚ C (Figure 2b), consistent with previous work (Boyken et al., 2016).
As expected, amantadine had no effect on the melting curve of 2L6HC3_13, suggesting the interac-
tions with ABP are through the designed binding site (Figure 2b). The circular dichroism (CD)
Figure 2. Binding characterization of amantadine to ABP. (a) SEC chromatogram monitoring absorbance at 280 nm (mAU) and estimated molecular
mass (from MALS). (b) Apo-ABP (orange, open circle) exhibits a high initial fluorescence signal that is lowered in the presence of amantadine (orange,
solid circle). As expected, 2LC3H6_13 (blue, open triangle) and 2LC3H6_13 plus amantadine (blue, solid triangle) exhibit a very low initial fluorescence
signal and overlap almost identically. (c) The CD spectrum of ABP at 25˚C, 75˚C, 95˚C, and 25˚C after heating and cooling. The CD spectrum of ABP at
25˚C suggests an all a-helical structure that remains fairly stable up to 75˚C. (d) 2D amide 1H-15N HMQC spectra (left) and 2D methyl 1H-13C HMQC
spectra (right) of 250 mM apo-ABP (red) or ABP in the presence of 2 mM amantadine (blue) recorded at 800 MHz, 37˚C. Titration of amantadine leads to
significant changes in the ABP NMR spectra (arrows). To the right of the 2D methyl methyl 1H-13C HMQC spectra an inset of dissociation constant
estimate through conventional fraction bound analysis is shown for the affected ILE methyl group, with an estimated KD of <55 mM. (e) NMR line shape
fitting of ABP throughout the NMR titration with amantadine performed in the program TITAN using a two-state binding model for the affected ILE
methyl group. The NMR data (gray) are shown versus the TITAN fit (magenta).
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. CD spectrum of ABP in the presence amantadine.
Figure supplement 2. NMR titration of ABP with amantadine.
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spectrum of ABP at 25˚ C suggests an all a-helical structure, with negative bands at 222 nm and 208
nm, and a positive band at 190 nm (Figure 2c). As the sample was heated to 95˚ C, a loss in CD sig-
nal was observed which was not significantly altered in the presence of 1 mM amantadine (Figure 2c
and Figure 2—figure supplement 1).
Solution NMR analysis of amantadine binding
To examine whether the hydrophobic residues (Ile-64, Leu-67, and Ala-68) contacting amantadine
(Figure 1b) undergo conformational changes upon ligand binding, as suggested by the thermofluor
assays, ABP was selectively 13C-methyl-labeled at Ala, Ile, Leu, and Val residues in a 12C/15N/1H
background and characterized by solution NMR, both in the presence and absence of amantadine.
We observe resonances for 70 out of 79 amide and 51 out of 51 methyl groups present in the pri-
mary sequence; a small number of amide NMR resonances are missing likely due to conformational
exchange-induced line broadening. The single set of peaks for all three polypeptide chains of the
apo-ABP suggests that it populates a homogeneous and symmetric ensemble of conformers in solu-
tion (Figure 2d). The 1H dispersion in the 2D 1H-15N HQMC and 2D 1H-13C HMQC NMR spectra
suggests that ABP, both in the presence and absence of amantadine, adopts a similar helical struc-
ture (Figure 2d). A full titration of amantadine on ABP confirms the formation of a stable amanta-
dine-ABP complex, with chemical exchange between the free and bound ABP states slow on the
NMR chemical shift time scale (residence time of 10–100 milliseconds) (Figure 2d, arrows). An NMR
line shape fitting of the three most significantly affected ABP methyl resonances (>0.1 ppm chemical
shift deviation between free and bound states) using TITAN suggest an apparent dissociation con-
stant (KD) of 24.1 ± 2.7 mM and upper limit for off-rate constant (koff) of 60.7 ± 5.6 s
 1 (on-rate con-
stant of 2.5  106 M 1 sec 1) (Figure 2e and Figure 2—figure supplement 2). The relatively slow
fitted on- and off-rate constants are consistent with a buried amantadine binding site. Fixing the KD
to half (12 mM) or twice (48 mM) the value obtained from the fit yielded higher chi-square residuals
and less good agreement between observed and simulated line shapes (Supplementary file 3). We
also performed an independent conventional fraction bound analysis, which yielded lower and upper
bounds for the KD to be 25 mM and 55 mM, respectively (Figure 2d, inset). Together, these data sug-
gest that amantadine likely binds to ABP with a KD in the low micromolar range. We were not able
to assign the resonances of the protein due to difficulties in preparing labeled samples, but we
observe significantly affected methyl resonances which could correspond to the Ile-64, Leu-67, and
Ala-68 residues in close proximity to the intended amantadine binding site in the designed structure
(Figure 1b). Together, the NMR titrations of both amide and methyl groups suggest the presence of
localized backbone and side-chain conformational changes in ABP upon amantadine binding.
X-ray crystal structure is in close agreement with the design model
We carried out crystallographic studies to characterize the interaction between ABP and amanta-
dine. Crystallization screen trays were set up with the same protein sample with or without ~five fold
molar excess amantadine (7.5 mM). Crystals were obtained in the presence but not the absence of
amantadine, consistent with ordering upon amantadine binding. The X-ray crystal structure of ABP
+amantadine was solved to 1.04 A˚, providing a high-resolution view of the ABP-amantadine com-
plex structure (Figure 3a and Supplementary file 2A). The crystal structure overlays well with the
design model, with an RMSD of 0.63 A˚ (TMAlign [Zhang and Skolnick, 2005]) (Figure 3a). The pri-
mary difference between the design model and crystal structure is in the compactness of helices in
the amantadine-binding region and rotation of the amantadine molecule accompanied by the pres-
ence of crystallographic water molecules (Figure 3a). In the original design model, the amino group
of amantadine was oriented to hydrogen bond directly to Ser-71 in ABP (Figure 3b), but in the X-ray
crystal structure, amantadine was found to be rotated 60˚ with ordered water molecules mediating
hydrogen bonds to Ser-71 residues in ABP (Figure 3b–c). Amantadine is often bound as a tri- or
tetra-hydrate with the waters associated with the amino group (Thomaston et al., 2018;
Wang et al., 2011), for example in a recent crystal structure of amantadine bound to the influenza
M2 channel protein, amantadine bound the key His-37 residues in M2 through water-mediated inter-
actions (Figure 3d). Including explicit water molecules in the Rosetta design calculations could
enable the design of proteins that bind amantadine with higher affinity.
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Neutron structure reveals hydrogen-bond interactions
We used neutron diffraction to directly visualize the intra- and intermolecular hydrogen-bond net-
works within ABP and with amantadine. Room temperature neutron data collected to 2.3 A˚ on a
deuterium-exchanged ABP crystal revealed the protonation state of residues that form hydrogen
bonds to the polar amino group of amantadine and the orientation of the D2O network that helps
anchor amantadine at the trimeric interface (Figure 3e–f; Supplementary file 2B). Nuclear scatter-
ing length density is clearly visible for the deuterium atoms of water molecules DOD-31 and DOD-
41, and the amino group of amantadine. DOD-31 accepts hydrogen bonds from the amino hydro-
gens of amantadine and donates hydrogen bonds to SER-71 and DOD-41. In both the X-ray and
neutron structures, amantadine sits at a special position on the C3 symmetry axis, with its adaman-
tane moiety interlocked at the trimeric interface and surrounded by the hydrophobic residues Ile-64,
Figure 3. Structural characterization of the ABP-amantadine interaction. (a) The high-resolution X-ray structure (white) and neutron structure (gray) of
ABP in complex with amantadine are very close to the computational model (magenta, green, and cyan) (RMSD of 0.63 A˚ and 0.59 A˚, respectively). The
blue arrow indicates the amantadine binding site shown in (c,e), and the red arrows indicate the hydrogen bond networks, one of which is shown in (f).
(b) A zoomed in overlay of the X-ray structure (white) and the design model (colored) reveal a shift in the helices within the amantadine-binding region,
accompanied by a ~ 60˚ rotation of amantadine and the presence of water molecules that that mediate hydrogen bonding to Ser-71. Yellow dashed
lines show direct hydrogen bonds to Ser-71 in the design model and black dashed lines show the hydrogen bonds observed in the X-ray structure. (c)
Clear electron density can be observed for amantadine and ordered water molecules in the binding site of ABP (2Fo - Fc map contoured at 1.0s).
Water-mediated hydrogen bonds are observed between Ser-71 and the amino group of amantadine (black dashed lines). (d) The crystal structure (pale
green) of amantadine bound to the influenza M2 protein through water-mediated hydrogen bonds (image generated from PDB: 6BKK
[Thomaston et al., 2018]). (e) The nuclear scattering length density map shows the positions of deuterium atoms, including two ordered water
molecules that mediate the hydrogen-bond network between Ser-71 and amantadine (2Fo - Fc contoured at 1.0s). Hydrogen bonds are shown as black
dashed lines. (f) Clear nuclear scattering length density can be observed for residues involved in the designed hydrogen-bond networks (black dashed
lines) in ABP (2Fo - Fc map contoured at 1.0s).
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Stereo images of the electron and neutron length scattering density maps for a hydrogen bond network in ABP.
Park et al. eLife 2019;8:e47839. DOI: https://doi.org/10.7554/eLife.47839 5 of 13
Short report Structural Biology and Molecular Biophysics
Leu-67, and Ala-68. The neutron structure shows no evidence of H/D exchange within the trimeric
interface, even though the crystals were D2O exchanged, suggesting that the trimeric core is tightly
packed, and that once formed, remains stable and inaccessible to solvent at room temperature.
ABP variant designs
ABP binds amantadine in a manner very similar to the design model and leads to significant localized
changes as visualized by solution NMR, but it is a constitutive (albeit perhaps not a very thermal-sta-
ble) trimer in the absence of amantadine. We sought to generate ABP derivatives with amantadine-
inducible trimerization by destabilizing the trimer in a variety of ways (Figure 1—figure supplement
1). Sidechain truncations such as Ala/Ser mutations were introduced in the core of ABP to destabilize
the trimeric interface (Figure 1—figure supplement 1b), but these constructs were either poorly
expressed or lost amantadine binding activity as assessed by thermofluor. The Rosetta HBNet proto-
col that was used to generate the hydrogen-bond networks in ABP was extended to search for inter-
molecular hydrogen bond interactions between residues that span the monomer-monomer
interfaces reduce the extent of hydrophobic packing of the trimer (Figure 1—figure supplement
1c), but these constructs were again poorly expressed. Truncations of the outer helix (Figure 1—fig-
ure supplement 1d–f) were attempted, but this resulted in mostly insoluble protein or monomeric
species that no longer bound amantadine (In one case, truncation of both helices (Figure 1—figure
supplement 1g) resulted in a tetramer that no longer bound amantadine). In larger-scale redesigns,
the core amantadine-binding site was backed up with helical repeat fusions to stabilize the helical
core (Figure 1—figure supplement 1h), but these constructs remained constitutive trimers. Taken
together, these results suggest that conversion of our design into well behaved monomers that
assemble into a trimer in the presence of amantadine is difficult because the subunit-subunit inter-
face in the trimer involves considerable non-polar surface area which makes the subunits poorly
behaved as monomers, and the low binding affinity for amantadine does not provide a strong driv-
ing force for assembly.
Discussion
We report the characterization of a de novo designed trimeric protein, ABP, which binds the small
molecule drug amantadine. The designed protein contains hydrogen-bond networks that specify the
trimeric state and water-mediated binding to amantadine. The solution NMR data suggest that ABP
adopts a stable, symmetric structure and readily binds amantadine. The high-resolution X-ray crystal
structure of the designed protein in complex with amantadine is very close to the computational
model, and the neutron structure demonstrates the presence of the designed hydrogen-bond net-
works. While we were unable to design an inducible trimer, our results are an advance for protein
design as to our knowledge this is the first successful de novo design of a homo-trimeric protein that
binds a C3 symmetric small molecule other than a metal ion (Mills et al., 2016). Our results suggest
two major bottlenecks to the goal of an amantadine-inducible trimerization system based on aman-
tadine binding at a helical bundle three-fold interface: (1) Amantadine, given its small size, does not
provide strong driving force for trimerization. (2) Well behaved monomers in the absence of amanta-
dine are hard to achieve in a system with substantial buried nonpolar surface area at the trimer inter-
face (which becomes exposed in the monomers). Success in designing protein homo-trimerization
systems will likely require smaller subunit interfaces and higher affinity binding sites, perhaps using
larger C3 molecules.
Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Strain, strain
background
(include species
and sex here)
One Shot
BL21 Star (DE3)
Chemically
Competent E. coli
Invitrogen
(Thermo Fisher
Scientific)
C601003
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Recombinant
DNA reagent
pET28b(+)
DNA - Novagen
Sigma-Aldrich
(Millipore Sigma)
69865–3
Commercial
assay or kit
NeXtal Tubes
JCSG+Suite
Qiagen 130720
Chemical
compound, drug
Amantadine
hydrochloride
Sigma-Aldrich
(Millipore Sigma)
A1260
Software,
algorithm
Rosetta
software suite
Rosetta Commons N/A
Rosetta design
Design calculations were performed using RosettaDesign. The Rosetta software suite is available
free of charge to academic users and can be downloaded from http://www.rosettacommons.org.
Instructions and inputs for running these applications, and all other data necessary to support the
results and conclusions (including the.xml,. cst,. params, and in.res files mentioned below), are pro-
vided in Supplementary files 1A-1D.
The initial 2LC3H6_13 scaffold was previously generated using parametric design (Boyken et al.,
2016). Briefly, the parametrically generated backbone was regularized using cartesian space minimi-
zation in Rosetta and a special instance of the HBNet protocol - HBNetStapleInterface - was used to
identify combinations of hydrogen-bond networks. The helices of monomer subunits were con-
nected into a single chain and the assembled proteins were designed using symmetric Rosetta
sequence design calculations in C3 symmetry.
In order to create the amantadine binding site, the RosettaScripts protocol was used with user-
defined design of the residue positions within 15 A˚ of the ligand (.xml). A Rosetta constraint (.cst)
file was used to specify the atom-pair constraints in amantadine. A molecule parameter (.params) file
was generated for amantadine in RosettaDesign. Amantadine was split into one third, and the nitro-
gen and carbon atoms on the axis of rotation were virtualized. Rotamers were repacked with Layer-
Design and resfile types (in.res) were used to specify Ser/Thr at residue positions hydrogen-bonding
to amantadine.
Cloning, protein expression and purification
ABP was cloned into the pET28b(+) vector at NdeI and XhoI restriction sites. The resulting expressed
protein sequence was as follows:
MGSSHHHHHHSSGLVPR/GSHMG//DAQDKLKYLVKQLERALRELKKSLDELERSLEELEKNPSEDALVE
NNRLNVENNKIIVEVLRIILELAKASAKLA
where ‘/’ demarks a thrombin cleavage site and ‘//’ demarks the beginning of the designed
sequence within Rosetta and the numbering of amino acids within this manuscript.
Constructs were transformed into BL21-Star (DE3) competent cells (Life Technologies). Cells har-
boring the plasmid were grown at 37˚C in Terrific Broth II medium containing a final concentration of
0.05 mg/ml kanamycin. Once cells reached an OD600 of 0.6–0.8, cells were cooled to 18˚C and
induced with 0.25 mM IPTG overnight. After this period, cells were harvested by centrifugation at
4000 r.p.m. for 10 min at 4˚C. Cell pellets were resuspended in 60 ml of 25 mM Tris (pH 8.0), 300
mM NaCl, 20 mM imidazole (pH 8.0), and 1 mM PMSF per 1 L of Terrific Broth II medium and stored
at  80˚C.
Cells were thawed in the presence of 0.25 mg/ml lysozyme and disrupted using sonication on ice
for 60 s. The cell extract was obtained by centrifugation at 13,000 r.p.m. for 30 min at 4˚C and was
applied onto Ni-NTA agarose beads (Qiagen) equilibrated with wash buffer (25 mM Tris (pH 8.0),
300 mM NaCl, and 20 mM imidazole (pH 8.0)). The wash buffer was used to wash the nickel column
three times with five column volumes. After washing, protein was eluted with five column volumes of
elution buffer (wash buffer with 300 mM imidazole).
The eluate was buffer-exchanged with SAXS buffer (25 mM Tris (pH 8.0), 150 mM NaCl, and 2%
glycerol) to lower the imidazole concentration from ~300 mM to <20 mM and cleaved with
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restriction-grade thrombin (EMD Millipore 69671–3) overnight at 20˚C. After overnight cleavage, the
sample was flowed over equilibrated Ni-NTA agarose beads and the flow-through was captured.
The protein sample was further purified by gel chromatography using a Superdex 75 Increase 10/
300 GL column (GE Healthcare) equilibrated with SAXS buffer. The fractions containing the protein
of interest were pooled and concentrated using a 3 K MWCO Amicon centrifugal filter (Millipore).
Thermofluor assay
Thermofluor assays were performed in SAXS buffer using a CFX96 Touch Real-Time PCR machine
(Bio-Rad). Thermal stability assays were performed using 45 ml of 5 mM protein (with or without 1
mM amantadine) and 5 mL of freshly prepared 200X SYPRO orange (Thermo-Fisher) solution in SAXS
buffer. The temperature was ramped from 25˚C to 95˚C in 0.5˚C increments with intervals of 5 s.
Fluorescence was read in the FRET scanning mode. The average of three replicates of buffer +
SYPRO orange solution (no protein control) was subtracted from the average of three replicates for
each sample.
Circular Dichroism
CD wavelength scans (260 to 195 nm) and temperature melts (25˚C to 95˚C) were measured using a
JASCO J-1500 or an AVIV model 420 CD spectrometer. Temperature melts monitored absorption
signal at 222 nm and were carried out at a heating rate of 4 ˚C/min. Protein samples were prepared
at 0.25 mg/mL in phosphate buffered saline (PBS) pH 7.4 in a 0.1 cm cuvette.
Solution NMR
Isotopically labeled ABP (U-[15N] Ala 13Cb, Ile 13Cd1, Leu 13Cd1/13Cd2, Val 13Cg1/13Cg2) methyl) was
prepared using well-established protocols (Tzeng et al., 2012) and buffer exchanged into NMR
buffer (50 mM NaCl, 20 mM sodium phosphate pH 6.5, 10% (v/v) D2O). Two-dimensional
1H-15N
SOFAST-HMQC and 1H-13C SOFAST-HMQC spectra of 250 mM ABP were recorded without amanta-
dine and with 2 mM amantadine at a 1H field of 800 MHz at 37˚C. The pH was monitored to ensure
that there were no pH changes that influence NMR shifts upon addition of amantadine hydrochlo-
ride. NMR titrations were performed using 118 mM ABP with 2D 1H-13C SOFAST-HMQC experimen-
tal readouts at a 1H field of 800 MHz at 37˚C with ABP:amantadine molar ratios of 1:0, 1:0.58, 1:1.35
and 1:2.47. Titration experiments were recorded with 16 scans with 38 msec acquisition in the indi-
rect 13C dimension and an interscan delay of 0.2 s. Data were processed with a 4 Hz and 10 Hz Lor-
entzian line broadening in the direct and indirect dimensions, respectively, and fit using a two-state
binding model in TITAN (Waudby et al., 2016) with bootstrap error analysis of 100 replicas. Identifi-
cation of methyl group types (ALA, ILE, LEU) was possible due to the unique chemical shift positions
of these methyl group types as referenced in the Biological Magnetic Resonance Data Bank (http://
www.bmrb.wisc.edu/). All NMR data were processed with NMRPipe (Delaglio et al., 1995) and ana-
lyzed using NMRFAM-SPARKY (Lee et al., 2015).
Crystallization of ABP
Purified ABP sample was concentrated to approximately 13 mg/ml in SAXS buffer and incubated
with 7.5 mM amantadine (~five fold molar excess). Samples were screened using the sparse matrix
method (Jancarik and Kim, 1991) with a Phoenix Robot (Art Robbins Instruments, Sunnyvale, CA)
utilizing the following crystallization screens: Morpheus (Molecular Dimensions), JCSG+ (Qiagen),
and Index (Hampton Research). Crystals were obtained in crystallization condition JCSG+ B9: 0.1 M
Citric Acid (4.0), 20% w/v PEG 6000 (final pH 5.0). Crystals were obtained after 1 to 14 days by the
sitting-drop vapor-diffusion method with the drops consisting of a 1:1 mixture of 0.2 mL protein solu-
tion and 0.2 mL reservoir solution.
X-ray diffraction collection and structure determination of ABP
ABP crystals were placed in a reservoir solution containing 20% (v/v) glycerol, and then flash-cooled
in liquid nitrogen. The X-ray data sets were collected at a wavelength of 1 A˚ at the Beamline 19-ID
of the Advanced Photon Source (APS) at Argonne National Laboratory (ANL). Data sets were
indexed and scaled using HKL2000 (Otwinowski and Minor, 1997). All the design structures were
determined by the molecular-replacement method with the program PHASER (McCoy et al., 2007)
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within the Phenix suite (Adams et al., 2010) using the design models as the initial search model.
The atomic positions obtained from molecular replacement and the resulting electron density maps
were used to build the design structures and initiate crystallographic refinement and model rebuild-
ing. Structure refinement was performed using the phenix.refine (Afonine et al., 2010) program.
Manual rebuilding using COOT (Emsley and Cowtan, 2004) and the addition of water molecules
allowed construction of the final models. Root-mean-square deviation differences from ideal geome-
tries for bond lengths, angles and dihedrals were calculated with Phenix (Adams et al., 2010). The
overall stereochemical quality of all final models was assessed using the program MOLPROBITY
(Davis et al., 2007). The model showed 100% of the residues in favorable regions of the Ramachan-
dran plot with 0% outliers. Figures were prepared with Pymol (Pymol Molecular graphics System,
Version 2.0; Schrodinger, LLC). Summaries of diffraction data and refinement statistics are provided
in Supplementary file 2A and a stereo image of a representative region of the electron density
map is shown in Figure 3—figure supplement 1a.
Neutron diffraction collection and structure refinement
Neutron sized ABP crystals were obtained by seeding/feeding techniques. Crystals were grown at
20˚C in sitting drops containing 3 ml protein solution mixed with 2 ml of the precipitant well solution,
which contained 9% PEG 6000, 0.1 M Citric acid pH 4.0. After 20 days, a 300-micron crystal was
transferred to a fresh drop containing 5 ml of precipitant and 3 ml of protein solution. After growth
terminated (20 days), 2–3 ml of protein solution was fed to the drop every two weeks. When the crys-
tal volume reached 0.2 mm3 (5 months), the well solution was replaced with a D2O containing
mother liquor 5 times to exchange labile hydrogen atoms with deuterium (4 months). The crystal
was mounted in a quartz capillary for data collection. Neutron diffraction data were recorded using
the IMAGINE instrument (Meilleur et al., 2013) at the High Flux Isotope Reactor at Oak Ridge
National Laboratory (ORNL). A total of 17 images at 34 hr exposure were collected from two crystal
orientations with 10˚ step intervals using a broad bandpass (2.8–4.5 A˚) quasi-Laue beam. Laue
images were indexed and integrated using the LAUEGEN (Campbell et al., 1998) suite of programs
from CCP4; wavelength normalized using LSCALE (Arzt et al., 1999) to account for the spectral dis-
tribution of the quasi-Laue beam and then scaled and merged using SCALA (Winn et al., 2011).
A room temperature X-ray diffraction data set was collected on a smaller crystal grown under the
same conditions and mounted in a quartz capillary at 293 K on a Rigaku micromax-007 HF X-ray gen-
erator with a Raxis IV++ image plate detector. The X-ray crystal structure was solved to a resolution
of 1.9 A˚ using Phenix and manual model building was performed using COOT. Isomorphous replace-
ment for neutron dataset was performed using Phenix with the protein model obtained from the 1.9
A˚ X-ray crystal structure followed by several cycles of atomic position and occupancy refinement.
The overall stereochemical quality of all final models was assessed using the program MOLPROBITY
(Davis et al., 2007). The model showed 98.6% of the residues in favorable regions of the Ramachan-
dran plot and 1.4% in the allowed region. Figures were prepared with Pymol (Pymol Molecular
graphics System, Version 2.0; Schrodinger, LLC). Summaries of diffraction data and refinement statis-
tics are listed in Supplementary file 2B and A stereo image of a representative region of the neu-
tron length scattering density map is shown in Figure 3—figure supplement 1b.
Data availability
The atomic coordinates and structure factors for the X-ray and neutron crystal structures of ABP
have been deposited in the RCSB Protein Data Bank under accession codes: 6N9H and 6NAF
respectively. All other data generated or analyzed during this study are included in this published
article (and its Supplementary files) or are available from the corresponding author on reasonable
request.
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